Document Detail


The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease.
MedLine Citation:
PMID:  22551881     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To examine the effect of combined calcium and vitamin D3 supplementation on bone mineral density (BMD) inpatients with chronic kidney disease (CKD).
METHODS: We performed a post-hoc analysis of the DECALYOS II, a 2-year randomized, double-blind, placebo-controlled study of 610 women randomized to: calcium-vitamin D3 fixed combination, calcium plus vitamin D3 separate combination, or placebo. Both active treatment groups received the same daily amount of calcium (1,200 mg) and vitamin D3 (800 IU). BMD of the distal radius was measured by single X-ray absorptiometry at baseline, 12 and 24 months.
RESULTS: At baseline 47.2%, 36.4% and 16.4% of the study population had an eGFR ≥ 60, 45 -59, and < 45 ml/min/1.73 m2, respectively. Both active regimens vs. placebo markedly increased serum 25-hydroxyvitamin D levels from baseline in all eGFR groups (p 0.22 for all time points).
CONCLUSION: Combined calcium and vitamin D3 supplementation was effective in reducing rate of BMD loss in women with moderate CKD.
Authors:
Cortney Bosworth; Ian H de Boer; Giovanni Targher; Jessica Kendrick; Gerard Smits; Michel Chonchol
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical nephrology     Volume:  77     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-03     Completed Date:  2012-06-26     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  358-65     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorptiometry, Photon
Age Factors
Analysis of Variance
Biological Markers / blood
Bone Density / drug effects*
Calcium / blood,  therapeutic use*
Chi-Square Distribution
Cholecalciferol / blood,  therapeutic use*
Chronic Disease
Dietary Supplements*
Double-Blind Method
Drug Combinations
Drug Therapy, Combination
Female
Glomerular Filtration Rate
Humans
Institutionalization
Kidney Diseases / blood,  drug therapy*,  physiopathology,  radiography
Placebos
Radius / drug effects*,  radiography
Time Factors
Treatment Outcome
Vitamin D / analogs & derivatives,  blood
Grant Support
ID/Acronym/Agency:
K23 DK087859/DK/NIDDK NIH HHS; KL2 TR000421/TR/NCATS NIH HHS; UL1 TR000423/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Drug Combinations; 0/Placebos; 1406-16-2/Vitamin D; 1C6V77QF41/Cholecalciferol; 64719-49-9/25-hydroxyvitamin D; SY7Q814VUP/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Normocalcemic hyperparathyroidism in patients with recurrent kidney stones: a disease entity or vita...
Next Document:  Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney...